drugset / Trial / NCT07535645
Baricitinib for Post-HSCT Persistent Thrombocytopenia
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, open-label phase 1b/2 clinical trial to explore the safety and efficacy profiles of baricitinib in patients with thrombopoietin-receptor-agonist-refractory persistent thrombocytopenia after allogeneic hematopoietic stem cell transplantation.
Timeline
- Start
- 2026-04-15
- Primary completion
- 2027-12-31
- Completion
- 2029-09-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Baricitinib | Small molecule | 2 mg | Oral |
| Subject | Baricitinib | Small molecule | 4 mg | Oral |